Literature DB >> 11996905

Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression.

R C Pereira1, A M Delany, Ernesto Canalis.   

Abstract

Bone marrow stroma contain pluripotential cells with the potential to differentiate into various mesenchymal cell lineages. We compared the effect of cortisol and bone morphogenetic protein-2 (BMP-2) on the differentiation of murine ST-2 stromal cells into mature osteoblasts or adipocytes. ST-2 cells were cultured for 3-27 days in the presence of 10% fetal bovine serum, 100 microg/mL ascorbic acid, and 5 mmol/L beta-glycerolphosphate in the presence or absence of cortisol at 1 micromol/L or BMP-2 at 1 nmol/L. Untreated ST-2 cells expressed high levels of alkaline phosphatase activity (APA) 15 days after confluence, and this was followed by the appearance of mineralized nodules after 24 days. BMP-2 accelerated and intensified the appearance of cells expressing APA and the presence of mineralized nodules. In contrast, cortisol decreased APA, prevented the formation of mineralized nodules, and induced a cellular phenotype characteristic of adipocytes. Untreated stromal cells expressed osteocalcin, Cbfa1, type I collagen, and alkaline phosphatase mRNA. BMP-2 increased osteocalcin and alkaline phosphatase mRNA, whereas cortisol suppressed their expression, as well as Cbfa1 and type I collagen transcripts. Cortisol enhanced, and BMP-2 downregulated, peroxisome proliferator-activated receptor gamma 2 and adipsin transcripts. The C/EBP transcription factors regulate genes critical for adipocytic and osteoblastic differentiation. Cortisol increased the expression of C/EBP alpha, beta, delta, and gamma mRNA levels, whereas BMP-2 had minor effects on C/EBP expression. In conclusion, BMP-2 accelerates the differentiation of stromal cells toward an osteoblastic phenotype, whereas glucocorticoids induce their differentiation toward an adipocytic phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996905     DOI: 10.1016/s8756-3282(02)00687-7

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  49 in total

Review 1.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 2.  Mechanisms of glucocorticoid action in bone.

Authors:  Ernesto Canalis
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

3.  Misexpression of CCAAT/enhancer binding protein beta causes osteopenia.

Authors:  Stefano Zanotti; Lisa Stadmeyer; Anna Smerdel-Ramoya; Deena Durant; Ernesto Canalis
Journal:  J Endocrinol       Date:  2009-02-13       Impact factor: 4.286

4.  A CCAAT/enhancer binding protein beta isoform, liver-enriched inhibitory protein, regulates commitment of osteoblasts and adipocytes.

Authors:  Kenji Hata; Riko Nishimura; Mio Ueda; Fumiyo Ikeda; Takuma Matsubara; Fumitaka Ichida; Kunihiro Hisada; Takashi Nokubi; Akira Yamaguchi; Toshiyuki Yoneda
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

5.  Glucocorticoids suppress bone formation via the osteoclast.

Authors:  Hyun-Ju Kim; Haibo Zhao; Hideki Kitaura; Sandip Bhattacharyya; Judson A Brewer; Louis J Muglia; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

6.  The influence of Leucine-rich amelogenin peptide on MSC fate by inducing Wnt10b expression.

Authors:  Xin Wen; William P Cawthorn; Ormond A MacDougald; Samuel I Stupp; Malcolm L Snead; Yan Zhou
Journal:  Biomaterials       Date:  2011-06-12       Impact factor: 12.479

Review 7.  TGF-β Family Signaling in Mesenchymal Differentiation.

Authors:  Ingo Grafe; Stefanie Alexander; Jonathan R Peterson; Taylor Nicholas Snider; Benjamin Levi; Brendan Lee; Yuji Mishina
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 8.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

Review 9.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

10.  First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

Authors:  Thomas Lund; Kent Søe; Niels Abildgaard; Patrick Garnero; Per T Pedersen; Tina Ormstrup; Jean-Marie Delaissé; Torben Plesner
Journal:  Eur J Haematol       Date:  2010-07-22       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.